Table 2.
Characteristics of the sample of late‐stage parkinsonism patients
| Characteristic | Value |
|---|---|
| Sample size, n | 625 |
| Women, n (%) | 284 (45.4) |
| Hoehn and Yahr score, n (%) | |
| Stage 2 | 5 (0.8) |
| Stage 2.5 | 14 (2.2) |
| Stage 3 | 30 (4.8) |
| Stage 4 | 362 (57.9) |
| Stage 5 | 214 (34.2) |
| Country, n (%) | |
| United Kingdom | 101 (16.1) |
| Germany | 152 (24.3) |
| France | 76 (12.2) |
| Sweden | 105 (16.8) |
| The Netherlands | 84 (13.4) |
| Portugal | 107 (17.1) |
| Self‐reported presence of dementia, n (%) | 237 (37.9) |
| Cognitive impairment defined as MMSE <26, n (%) | 402 (53.5) |
| Self‐reported diagnosis of Parkinson's disease, n (%) | 546 (87.4) |
| Current psychotropic drug use, n (%) | |
| Any psychotropic drug | 423 (67.7) |
| Antidepressant | 235 (37.6) |
| SSRI | 109 (17.4) |
| Mirtazepine | 53 (8.5) |
| Tricyclic | 20 (3.2) |
| Venlafaxine | 19 (3.0) |
| Other | 34 (5.4) |
| Anxiolytic | 66 (10.6) |
| Psychostimulant | 3 (0.4) |
| Antipsychotic | 156 (25.0) |
| Quetiapine | 88 (14.1) |
| Clozapine | 65 (10.4) |
| Typical (contra‐indicated) | 3 (0.5) |
| Antidementia drug | 159 (25.4) |
| Rivastigmine | 118 (18.9) |
| Memantine | 42 (6.7) |
| Donezepil | 14 (2.2) |
| Hypnotic | 125 (20.0) |
| Age, median (min–max) | 77 (24–96) |
| Disease duration in years, median (min–max) | 14 (7–62) |
| Years of education, median (min–max) | 9 (0–25) |
| Schwab and England score, median (min–max) | 30 (0–80) |
| Levodopa equivalent daily dose, median (min–max) | 815 (0–4834) |
Abbreviations: MMSE, Mini Mental State Examination; SSRI, selective serotonin reuptake inhibitor.